<DOC>
	<DOC>NCT00186667</DOC>
	<brief_summary>Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.</brief_summary>
	<brief_title>Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease</brief_title>
	<detailed_description>An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant</detailed_description>
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>active chronic GvHD ANC &gt; 1000/mm^3 therapeutic cyclosporine uncontrolled systemic infection elevated serum creatinine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>